Armata Pharmaceuticals Files 8-K

Ticker: ARMP · Form: 8-K · Filed: Dec 19, 2024 · CIK: 921114

Armata Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyArmata Pharmaceuticals, INC. (ARMP)
Form Type8-K
Filed DateDec 19, 2024
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Armata Pharma dropped an 8-K with Reg FD disclosure and financials - check it out.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details regarding the nature of the disclosure or exhibits.

Why It Matters

This 8-K filing indicates that Armata Pharmaceuticals has made a regulatory disclosure and submitted financial statements and exhibits, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

FAQ

What specific information was disclosed under Regulation FD?

The filing does not specify the content of the Regulation FD disclosure.

What financial statements and exhibits were filed?

The filing indicates that financial statements and exhibits were submitted, but their specific contents are not detailed in this summary.

What is the primary purpose of this 8-K filing?

The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.

What is Armata Pharmaceuticals' principal executive office address?

The principal executive offices are located at 5005 McConnell Avenue, Los Angeles, California 90066.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number is 91-1549568.

Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-12-19 07:38:42

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On December 19, 2024, Armata Pharmaceuticals, Inc. (the " Company ") issued a press release announcing results from its Phase 2 Tail wind study of inhaled AP-PA02 in non-cystic fibrosis bronchiectasis subjects with chronic pulmonary Pseudomonas aeruginosa infection. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company posted an updated corporate presentation dated December 19, 2024 (the " Corporate Presentation ") to its website at https://investor.armatapharma.com/events-and-presentations. The Corporate Presentation, which is furnished as Exhibit 99.2 hereto, replaces the corporate presentation dated November 15, 2024 previously posted to the Company's website. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated. The information contained in the Corporate Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (" SEC ") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the Company disclaims any inferences regarding the materiality of such information that may arise as a result of it furnishing such information under Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 and the atta

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated December 19, 2024. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2024 Armata Pharmaceuticals, Inc. By: /s/ David D. House Name: David D. House Title: Senior Vice President, Finance and Principal Financial officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing